Skip to main content
NXTS
NASDAQ Life Sciences

Nexentis Technologies Swaps KPMG Israel for Deloitte Israel Amid Going Concern Warning

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.925
Mkt Cap
$2.798M
52W Low
$1.43
52W High
$61.25
52W Position info
35% above low
Off High info
97% below high
Rel. Volume
Market data snapshot near publication time

NXTS sits 35% above its 52-week low of $1.43.

Summary

Nexentis Technologies replaced its independent auditor, dismissing KPMG Israel and engaging Deloitte Israel, effective August 6, 2026. The change occurs against a backdrop of going concern warnings and financial distress.


Key Events · Corporate Governance and Compliance · NXTS

  • Auditor Dismissal

    Effective August 6, 2026, KPMG Israel was dismissed as independent auditor. While no disagreements were reported, prior audit reports included a going concern paragraph.

  • New Auditor Appointed

    Deloitte Israel has been engaged to audit the fiscal year 2026 financial statements, with no prior consultations on accounting or auditing matters.

  • Going Concern Context

    Recurring losses and a net capital deficiency raise substantial doubt about the company's ability to continue as a going concern.

  • Recent Financial Distress

    This follows multiple dilutive offerings in June 2026 totaling over $4 million, a $6.6 million Q1 net loss, and a reverse stock split in April 2026.


Analysis · NXTS · Life Sciences

On August 6, 2026, Nexentis Technologies dismissed its auditor KPMG Israel and appointed Deloitte Israel. The company faces a going concern warning, recurring losses, and a net capital deficiency. An auditor change at a distressed company often signals potential disagreements over accounting or a search for a more accommodating auditor, though the filing states no disagreements. The move comes after a series of dilutive financings and a recent reverse stock split, adding governance uncertainty.

At the time of this filing, NXTS was trading at $1.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $1.43 to $61.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NXTS - Latest Insights

NXTS
Jul 13, 2026, 4:05 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $3.10
Real-time Price: $1.93 info
Change: -$1.18 (-38%) info
Market Cap: $2.798M info
NXTS
Jun 29, 2026, 8:20 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.47
Real-time Price: $1.93 info
Change: -$3.55 (-65%) info
Market Cap: $2.798M info
NXTS
Jun 23, 2026, 10:03 AM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $5.96
Real-time Price: $1.93 info
Change: -$4.04 (-68%) info
Market Cap: $2.798M info
NXTS
Jun 22, 2026, 4:53 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $7.95
Real-time Price: $1.93 info
Change: -$6.03 (-76%) info
Market Cap: $2.798M info
NXTS
Jun 22, 2026, 4:49 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $9.00
Real-time Price: $1.93 info
Change: -$7.08 (-79%) info
Market Cap: $2.798M info